Tripegfilgrastim

DRUG2 trials

Sponsors

Dong-A ST Co., Ltd., National Cancer Center, Korea

Conditions

LymphomaSolid TumorUnresectable Bile Duct CarcinomaUnresectable Biliary Tract CarcinomaUnresectable Pancreatic Cancer

Phase 1

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Tripegfilgrastim in Pediatric Solid Tumor/Lymphoma Patients

CompletedNCT02963389

Dong-A ST Co., Ltd.Lymphoma, Solid Tumor

Start: 2016-10-04End: 2018-11-30Updated: 2019-01-15

Phase 2

Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers

RecruitingNCT06135896

National Cancer Center, KoreaUnresectable Bile Duct Carcinoma, Unresectable Biliary Tract Carcinoma, Unresectable Pancreatic Cancer

Start: 2024-01-16End: 2026-06-30Target: 98Updated: 2025-06-18

Related Papers

Pharmacokinetic and Pharmacodynamic Characteristics of Tripegfilgrastim, a Pegylated G‐CSF, in Pediatric Patients with Solid Tumors

Clinical Pharmacology & Therapeutics2021-10-051 citations

A Phase I Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Tripegfilgrastim (Dulastin®) after Single Administration in Pediatric Patients

Blood2019-11-13